Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Breast Neoplasms 543Triple Negative Breast Neoplasms 97Ovarian Neoplasms 58Colorectal Neoplasms 50Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 44Neoplasms 38Lung Neoplasms 33Melanoma 29Endometrial Neoplasms 29Neoplasm Metastasis 28Stomach Neoplasms 26Pancreatic Neoplasms 26Uterine Cervical Neoplasms 25Squamous Cell Carcinoma of Head and Neck 22Colonic Neoplasms 20Head and Neck Neoplasms 18Carcinoma, Renal Cell 18Esophageal Neoplasms 16Sarcoma 14Advanced Breast Cancer 14Small Cell Lung Carcinoma 13Urinary Bladder Neoplasms 12Liver Neoplasms 11Carcinoma, Transitional Cell 11Kidney Neoplasms 10Carcinoma, Intraductal, Noninfiltrating 10Brain Neoplasms 10Lymphedema 9Anatomic Stage I Breast Cancer AJCC v8 9

Interventions

trastuzumab deruxtecan 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Breast × 30 days × Clear all
NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Recruiting
70 enrolled
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon ⚡